Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Beyond Air ( (XAIR) ) has issued an announcement.
Beyond Air, Inc. announced on February 5, 2025, that it received an additional 180-day extension from Nasdaq to meet the minimum bid price requirement of $1 per share, which is crucial for maintaining its listing on the Nasdaq Capital Market. Despite failing to comply within the initial period ending February 4, 2025, the company was granted more time due to its compliance with other listing criteria and plans to address the deficiency, potentially through a reverse stock split. The extension allows the company’s stock to continue trading without immediate impact while efforts are made to regain compliance, with the risk of delisting if compliance is not achieved by August 4, 2025.
More about Beyond Air
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company focused on leveraging nitric oxide (NO) to treat respiratory illnesses, neurological disorders, and solid tumors. The company has FDA approval for its LungFit PH system for neonates with respiratory failure and is advancing other LungFit systems in clinical trials for severe lung infections. Beyond Air is also involved in pre-clinical programs for autism spectrum disorder in partnership with The Hebrew University of Jerusalem, and its affiliate, Beyond Cancer, Ltd., is exploring NO’s anti-cancer properties in solid tumors.
YTD Price Performance: 8.33%
Average Trading Volume: 1,277,286
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $29.65M
See more insights into XAIR stock on TipRanks’ Stock Analysis page.
